Literature DB >> 12816927

Detection of anti-livin antibody in gastrointestinal cancer patients.

Atsuhito Yagihashi1, Koichi Asanuma, Naoki Tsuji, Toshihiko Torigoe, Noriyuki Sato, Koichi Hirata, Naoki Watanabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12816927     DOI： 10.1373/49.7.1206

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  12 in total

1.  Isoform-specific silencing of the Livin gene by RNA interference defines Livin beta as key mediator of apoptosis inhibition in HeLa cells.

Authors:  Irena Crnković-Mertens; Julia Semzow; Felix Hoppe-Seyler; Karin Butz
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

2.  Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma.

Authors:  Toshiaki Tanaka; Hiroshi Kitamura; Toshihiko Torigoe; Yoshihiko Hirohashi; Eiji Sato; Naoya Masumori; Noriyuki Sato; Taiji Tsukamoto
Journal:  J Cancer Res Clin Oncol       Date:  2010-07-31       Impact factor: 4.553

Review 3.  Research progress on Livin protein: an inhibitor of apoptosis.

Authors:  Biao Yan
Journal:  Mol Cell Biochem       Date:  2011-05-27       Impact factor: 3.396

4.  Diagnostic relevance of autoantibody detection against inhibitors of apoptosis proteins in colon cancer and colon adenoma.

Authors:  Yukie Hosono; Maki Goto; Daisuke Kobayashi; Kageaki Kuribayashi; Maki Tanaka; Naoki Watanabe
Journal:  Mol Clin Oncol       Date:  2015-02-06

5.  siRNA directed against Livin inhibits tumor growth and induces apoptosis in human glioma cells.

Authors:  Bangqing Yuan; Boli Ran; Shousen Wang; Zheng Liu; Zhaocong Zheng; Hongjie Chen
Journal:  J Neurooncol       Date:  2011-11-16       Impact factor: 4.130

Review 6.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

7.  Livin and Bcl-2 expression in high-grade osteosarcoma.

Authors:  T Nedelcu; B Kubista; A Koller; I Sulzbacher; I Mosberger; F Arrich; K Trieb; R Kotz; C D Toma
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-14       Impact factor: 4.553

8.  Calreticulin is a B cell molecular target in some gastrointestinal malignancies.

Authors:  A Pekáriková; D Sánchez; L Palová-Jelínková; M Simsová; Z Benes; I Hoffmanová; P Drastich; I Janatková; T Mothes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2009-12-17       Impact factor: 4.330

9.  Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.

Authors:  Jun Zhou; Noah K Yuen; Qian Zhan; Elsa F Velazquez; George F Murphy; Anita Giobbie-Hurder; F Stephen Hodi
Journal:  Cancer Immunol Immunother       Date:  2011-10-28       Impact factor: 6.968

Review 10.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).

Authors:  Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg
Journal:  Apoptosis       Date:  2017-07       Impact factor: 4.677
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.